🇺🇸 FDA
Patent

US 9364535

Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject

granted A61KA61K2039/507A61K35/30

Quick answer

US patent 9364535 (Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject) held by The Regents of the University of California expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jun 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K2039/507, A61K35/30, A61K39/3955